Loomis, Sayles & Company
ENZ

Loomis, Sayles & Company’s Enzo Biochem, Inc. ENZ Stock Holding History

Loomis, Sayles & Company’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-417
Closed -$5K – 982
2017
Q2 		$5K Hold
417
– – ﹤0.01% 868
2017
Q1 		$3K Hold
417
– – ﹤0.01% 917
2016
Q4 		$3K Buy
+417
New +$2.66K ﹤0.01% 963

Other funds holding ENZ

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EGA
Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company's ENZ Position: Q3 2017 in Review

Loomis, Sayles & Company sold out of Enzo Biochem, Inc. (ENZ) in Q3 2017, closing a stake of 417 shares — an estimated $5K sold.

Loomis, Sayles & Company first reported a position in ENZ in Q4 2016 and held it in 3 quarters. The position peaked at $5K in Q2 2017. 116 funds tracked by Wall St. Rank hold ENZ as of Q3 2017.

  • Loomis, Sayles & Company reported no remaining Enzo Biochem, Inc. position as of Q3 2017 after selling out during the quarter.
  • Loomis, Sayles & Company sold 417 Enzo Biochem, Inc. shares in Q3 2017, an estimated $5K.
  • Loomis, Sayles & Company first reported a position in Enzo Biochem, Inc. in Q4 2016 and held it in 3 quarters.
  • Loomis, Sayles & Company's Enzo Biochem, Inc. position peaked at $5K in Q2 2017.
  • 116 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q3 2017.

Based on Loomis, Sayles & Company's 13F filing for Q3 2017, filed 14 Nov 2017.